However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

Hyperglycemia was most often associated with an unwillingness of providers to take responsibility for diabetes management and the exclusive use of sliding-scale insulin regimens. Conclusion ...

(Figure 1) Given below are recombinant products that could be candidates for biosimilars: Recombinant Proteins: Insulin human (1982-2019); somatropin ... alefacept (2003); laronidase (2003); insulin ...

Patients on SS insulin received a traditional SS regimen with regular insulin or insulin aspart based on physician preference. Results: Demographics and comorbidities were similar between the 2 ...

“The product has a patented spring-loaded system that drives insulin through a small opening in a nozzle, virtually pain free.” The device uses high pressure dispersion through the skin.